Harvard Bioscience, Inc.

HBIO

US4169061052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
3.16 ^USD	-0.63%		-6.23%	-40.93%

05-07	Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M	MT

Harvard Bioscience, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

November 08, 2022 at 04:01 pm

Harvard Bioscience, Inc. provided earnings guidance for the fourth quarter of 2022. For the quarter, the company expects sequential revenue growth. Revenue to be in the $30 million range.

Latest news about Harvard Bioscience, Inc.

Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M	05-07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 EPS $0.02	05-07	MT
Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024	05-07	CI
Harvard Bioscience Reducing Headcount	04-09	MT
Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth	04-09	CI
Harvard Bioscience, Inc. Enters into A Third Amendment to the Credit Agreement	04-03	CI
Transcript : Harvard Bioscience, Inc., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 Revenue $28.2M	03-07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 EPS $0.04	03-07	MT
Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024	03-07	CI
Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-07	CI
North American Morning Briefing : Powell Still in -2-	03-07	DJ
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting	03-06	CI
Transcript : Harvard Bioscience, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Revenue $25.4M	11-07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 EPS $0.01	11-07	MT
HARVARD BIOSCIENCE INC - REMAIN ON PATH TO REDUCING NET LEVERAGE…	11-07	RE
Harvard Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023	11-07	CI
Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference	11-06	CI
Harvard Bioscience Unit Named as Exclusive Distributor of Etisense's Cardiorespiratory Monitoring Product	23-09-18	MT
Insider Buy: Harvard Bioscience	23-08-21	MT
Harvard Bioscience Seeks Acquisitions	23-08-08	CI

Chart Harvard Bioscience, Inc.

Duration

Period

More charts

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harvard Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.16 USD

Average target price

7 USD

Spread / Average Target

+121.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HARVARD BIOSCIENCE, INC.	-40.93%	137M
THERMO FISHER SCIENTIFIC	+10.03%	223B
DANAHER CORPORATION	+13.59%	195B
INTUITIVE SURGICAL, INC.	+20.01%	144B
BOSTON SCIENTIFIC CORPORATION	+30.83%	111B
SIEMENS HEALTHINEERS AG	+2.05%	65.01B
EDWARDS LIFESCIENCES CORPORATION	+15.38%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	50.45B
AGILENT TECHNOLOGIES, INC.	+8.37%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	36.45B

Other Advanced Medical Equipment & Technology